Tower Research Capital (TRC)’s Moleculin Biotech MBRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$9.8K Buy
176
+84
+91% +$4.29K ﹤0.01% 4011
2026
Q1
$4.2K Buy
92
+22
+31% +$1.46K ﹤0.01% 4224
2025
Q4
$4.61K Buy
70
+53
+312% +$9.9K ﹤0.01% 4199
2025
Q3
$4.44K Buy
17
+9
+113% +$2.43K ﹤0.01% 4349
2025
Q2
$1.18K Buy
8
+5
+167% +$2.05K ﹤0.01% 4856
2025
Q1
$1.31K Sell
3
-5
-63% -$3.36K ﹤0.01% 4740
2024
Q4
$6.84K Buy
8
+4
+100% +$4.85K ﹤0.01% 4136
2024
Q3
$5.14K Hold
4
– – ﹤0.01% 4322
2024
Q2
$7.02K Buy
4
+3
+300% +$6.93K ﹤0.01% 4507
2024
Q1
$3.67K Hold
1
– – ﹤0.01% 4822
2023
Q4
$6.18K Sell
1
-1
-50% -$4.15K ﹤0.01% 4775
2023
Q3
$6.12K Hold
2
– – ﹤0.01% 4642
2023
Q2
$8.32K Hold
2
– – ﹤0.01% 4446
2023
Q1
$12K Buy
2
+1
+100% +$8.76K ﹤0.01% 4097
2022
Q4
$6K Hold
1
– – ﹤0.01% 4733
2022
Q3
$10K Hold
1
– – ﹤0.01% 4546
2022
Q2
$6K Hold
1
– – ﹤0.01% 4936
2022
Q1
$7K Buy
+1
New +$11.5K ﹤0.01% 4737
2021
Q4
– Hold
0
– – – 6381
2021
Q3
– Hold
0
– – – 5998
2021
Q2
– Hold
0
– – – 4438
2021
Q1
– Hold
0
– -$7K – 5577
2020
Q4
– Hold
0
– – – 4496
2019
Q4
– Hold
0
– -$1K – 4031
2019
Q3
– Hold
0
– – – 3890
2017
Q2
– Hold
0
– -$4K – 3143
2017
Q1
– Hold
0
– – – 2324
2016
Q4
– Hold
0
– – – 4172
2016
Q3
– Hold
0
– – – 2559
2016
Q2
– Hold
0
– – – 2924

Other funds holding MBRX

Tower Research Capital (TRC)'s MBRX Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Moleculin Biotech (MBRX) stake by 91% in Q2 2026, buying an estimated $4.29K and bringing the position to 176 shares worth $9.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4011.

Tower Research Capital (TRC) first reported a position in MBRX in Q1 2022 and has held it in 18 quarters since. The position peaked at $12K in Q1 2023. 15 funds tracked by Wall St. Rank hold MBRX as of Q2 2026.

  • Tower Research Capital (TRC) held 176 shares of Moleculin Biotech worth $9.8K as of Q2 2026.
  • Tower Research Capital (TRC) bought 84 Moleculin Biotech shares in Q2 2026, an estimated $4.29K.
  • Moleculin Biotech made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4011 holding.
  • Tower Research Capital (TRC) first reported a position in Moleculin Biotech in Q1 2022 and has held it in 18 quarters since.
  • Tower Research Capital (TRC)'s Moleculin Biotech position peaked at $12K in Q1 2023.
  • 15 funds tracked by Wall St. Rank held Moleculin Biotech as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.